Stockholm, March 17, 2023. Redwood Pharma AB (publ) announces that the company has now completed recruitment and the last person has been included in the clinical study for RP501, the company's medical technology self-care product that is being developed for the treatment of dry eyes. The topline results from the study are expected to be presented at the end of the second quarter of 2023.
The study evaluates the safety, tolerability and effect of the treatment in people suffering from dry eyes, with or without the use of contact lenses. The study consists of two groups, without or with contact lenses and patients have been treated for 90 and 30 days, respectively. The study results will be the basis for Redwood Pharma's application for CE marking with a notified body.
"Recruitment for the study has now been successfully completed in line with the schedule that we have previously communicated. We are now working purposefully to move forward with our innovative dry eye treatment, RP501, towards a market launch so that we can start generating revenue for the company", comments Martin Vidaeus, CEO of Redwood Pharma.
RP501 is being developed to be an effective over-the-counter artificial tear for the relief of dry eye, a condition that affects more than 300 million people worldwide. RP501 is based on IntelliGel - a patented and unique formulation that has the consistency of a drop of water when instilled into the eye, where it instantly transforms into a viscous, protective and lubricating film.
For further information
Martin Vidaeus - CEO, Phone: +46 70-232 29 29
Email:martin.vidaeus@redwoodpharma.com
About Redwood Pharma
Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) is developing next-generation treatments for dry eye disease. More than 300 million people suffer from dry eyes and today's standard treatment provides only temporary relief and may need to be applied up to ten times a day. Redwood Pharma's development projects are based on IntelliGel - a proprietary and unique formulation of polymers and water that has the consistency of a water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that stays on for an extended period of time. The company currently has two development projects: RP501 as a readily available medical device for the treatment of mild dry eye disease, and the drug candidate RP101 containing estrogen for the treatment of postmenopausal dry eye disease in women. The company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, Sweden (+46 8 463 80 00, certifiedadviser@penser.se).Formore information, please visit www.redwoodpharma.se